SCHEMBL6851333

SCHEMBL6851333

O=C(Cc1ccc(Cl)cc1)NCC1CCc2ncn(C(c3ccccc3)(c3ccccc3)c3ccccc3)c2C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 5/20 0.41
FAAH O00519 1/20 0.39
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
KCNQ2 O43526 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
GRM7 Q14831 1/20 0.38
NPBWR1 P48145 1/20 0.37
MCHR1 Q99705 1/20 0.37
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
POLB P06746 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
GAA P10253 1/20 0.36
KCNH2 Q12809 1/20 0.36
CACNA1I Q9P0X4 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6846987 0.93 CCR2 (0.41) CCR2FAAHBCHEACHEKCNQ2
SCHEMBL6849628 0.91 CCR2 (0.41) CCR2FAAHBCHEACHEPOLB
SCHEMBL6849558 0.84 CCR2 (0.41) CCR2FAAHBCHEACHEPOLB
SCHEMBL7009826 0.83 MTNR1A (0.43)
SCHEMBL6849769 0.82 CCR2 (0.43) CCR2FAAHBCHEACHELMNA
SCHEMBL6851108 0.74 LMNA (0.41) LMNAMAPTSMN1; SMN2GAAMEN1
SCHEMBL7009824 0.74 HSD11B1 (0.32) BCHEACHELMNASMN1; SMN2MEN1
SCHEMBL7652744 0.73 GRM7 (0.38) CCR2FAAHBCHEACHEKCNQ2
SCHEMBL1417680 0.71 PDK1 (0.34) KDM4E
SCHEMBL6849610 0.70 LMNA (0.43) GRM7POLBLMNATP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6756384-B2 TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. NOVO NORDISK A/S (DK) 2004-06-29 US disclosed
US-20030135056-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2003-07-17 US disclosed
US-6437147-B1 FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM NOVO NORDISK (DK) 2002-08-20 US disclosed
US-20020058659-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2002-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030135056-A1 Imidazole compounds HRH3, HRH4, HRH2 CCR2 707/4885FAAH 386/4885BCHE 215/4885
US-20020058659-A1 Imidazole compounds HRH3, HRH4, HRH2 CCR2 707/4885FAAH 386/4885BCHE 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.